17,953 Shares in Medtronic PLC $MDT Bought by Fideuram Asset Management Ireland dac

Posted by Brian Himes on May 30th, 2026

Fideuram Asset Management Ireland dac bought a new position in Medtronic PLC (NYSE:MDT – Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 17,953 shares of the medical technology company’s stock, valued at approximately $1,652,000.

A number of other hedge funds have also added to or reduced their stakes in the stock. Lodestone Wealth Management LLC bought a new position in shares of Medtronic in the 4th quarter worth approximately $27,000. Anfield Capital Management LLC grew its position in shares of Medtronic by 410.7% in the 4th quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock worth $27,000 after buying an additional 230 shares during the period. Valley Wealth Managers Inc. bought a new position in Medtronic in the 3rd quarter worth about $29,000. Board of the Pension Protection Fund bought a new position in Medtronic in the 4th quarter worth about $29,000. Finally, GoalVest Advisory LLC bought a new position in Medtronic in the 4th quarter worth about $29,000. 82.06% of the stock is owned by hedge funds and other institutional investors.

Medtronic Trading Down 2.4%

Shares of MDT opened at $73.73 on Friday. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.54 and a quick ratio of 1.87. Medtronic PLC has a 1 year low of $73.67 and a 1 year high of $106.33. The company has a 50 day simple moving average of $82.36 and a two-hundred day simple moving average of $92.65. The firm has a market cap of $94.66 billion, a P/E ratio of 20.54, a price-to-earnings-growth ratio of 1.80 and a beta of 0.62.

Medtronic Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, April 17th. Investors of record on Friday, March 27th were issued a $0.71 dividend. The ex-dividend date of this dividend was Friday, March 27th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.9%. Medtronic’s dividend payout ratio (DPR) is 79.11%.

Wall Street Analysts Forecast Growth

MDT has been the topic of several research analyst reports. Argus lowered their target price on shares of Medtronic from $125.00 to $115.00 and set a “buy” rating on the stock in a research note on Monday, April 6th. Needham & Company LLC restated a “buy” rating and set a $120.00 target price on shares of Medtronic in a research note on Thursday, March 26th. Robert W. Baird upped their target price on shares of Medtronic from $92.00 to $93.00 and gave the company a “neutral” rating in a research note on Wednesday, April 15th. Stifel Nicolaus lowered their price objective on shares of Medtronic from $105.00 to $95.00 and set a “hold” rating on the stock in a research note on Monday, April 6th. Finally, CICC Research initiated coverage on shares of Medtronic in a research note on Friday, January 30th. They issued an “outperform” rating on the stock. Fifteen equities research analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Medtronic has a consensus rating of “Moderate Buy” and an average price target of $106.45.

View Our Latest Stock Report on Medtronic

Medtronic Company Profile

(Free Report)

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).